Shenzhen Proxinse Medical Technology Co., Ltd, a provider of minimally invasive surgery endoscope camera systems based in China, has reportedly raised “tens of millions” of renminbi in a Series A financing round. The round was led by Guangdong Technology Financial Group, with participation from Shenzhen HTI Group and Zhongshan Huoju Huaying Investment. The proceeds will be used to expand the core research and development (R&D) team, improve product layout, and invest in market development.
Company Background and Product Development
Founded in 2017, Proxinse Medtech has extensive experience in image/video algorithms, software and hardware development, and marketing management. The company has developed numerous products, including image processing main board modules and other components. Its core product, the 3D electronic laparoscope (30°), obtained market approval in June of this year and is expected to be launched soon. This product is designed to enhance surgical precision and efficiency in minimally invasive procedures.
Market Outlook
Statistics indicate that the market for endoscope equipment in China may be valued at RMB 42.27 billion (USD 5.87 billion) by 2024, accounting for 22.7% of the global market. This growth underscores the significant potential for Proxinse Medtech’s products, as the company aims to capture a larger share of this expanding market.
Future Outlook
The Series A financing round highlights Proxinse Medtech’s commitment to advancing its minimally invasive surgery technology. By leveraging the new funds, the company aims to enhance its R&D capabilities, expand its product portfolio, and strengthen its market presence in the rapidly growing field of endoscope equipment.-Fineline Info & Tech
